Table 1 Functional validation of purified DRPs
| Â | Functional test | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Disulfide Rich Peptide | Fold | SS | DsbC fusion produced (mg/L) | Theoretical DRP (mg/L) | Purified DRP (mg/L) | DRP yield | Detected mass | Test | Observed vs Expected |
mCD4M61 | α/β | 3 | 90 | 8.9 | 3.5 | 39% | 2972.0 ± 0.5 | ELISA | 69 nM (32 nM) |
Trypsin Inhibitor II | ICK | 3 | 291 | 30.1 | 0.9 | 3% | 3124.4 ± 0.3 | Trypsin Inhibition | 1.0 nM (0.3 nM) |
LDTI | Kazal Type | 3 | 240 | 35.0 | 12.0 | 34% | 4572.1 ± 0.1 | Trypsin Inhibition | 1.8 nM (1.8 nM) |
Thrombin Inhibitor Infestin | Kazal Type | 3 | 120 | 20.2 | 0.8 | 4% | 5507.7 ± 0.2 | Trypsin Inhibition | 1.8 nM (2 nM) |
BPTI | Kunitz | 3 | 180 | 35.1 | 3.0 | 9% | 6567.6 ± 0.1 | Plasmin inhibition | 0.4 nM (0.14 nM) |
MT7 | 3FT | 4 | 160 | 34.7 | 0.007 | < 0.03% | 7529.9 ± 0.6 | binding mAChR | 5 pM (29 pM) |